Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $8.4 million.

  • Myriad Genetics' Change in Accured Expenses rose 2727.27% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.3 million, marking a year-over-year increase of 3374.49%. This contributed to the annual value of -$41.0 million for FY2024, which is 25073.53% down from last year.
  • As of Q3 2025, Myriad Genetics' Change in Accured Expenses stood at $8.4 million, which was up 2727.27% from -$16.8 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Change in Accured Expenses high stood at $71.9 million for Q2 2023, and its period low was -$59.4 million during Q4 2023.
  • Moreover, its 5-year median value for Change in Accured Expenses was -$5.5 million (2024), whereas its average is -$2.9 million.
  • As far as peak fluctuations go, Myriad Genetics' Change in Accured Expenses plummeted by 700000.0% in 2021, and later surged by 434000.0% in 2023.
  • Over the past 5 years, Myriad Genetics' Change in Accured Expenses (Quarter) stood at -$14.2 million in 2021, then soared by 80.28% to -$2.8 million in 2022, then tumbled by 2021.43% to -$59.4 million in 2023, then skyrocketed by 53.7% to -$27.5 million in 2024, then skyrocketed by 130.55% to $8.4 million in 2025.
  • Its Change in Accured Expenses stands at $8.4 million for Q3 2025, versus -$16.8 million for Q2 2025 and -$12.4 million for Q1 2025.